share price, page-15

DNDN has been smashed over the past year or so because of poor management, high cost of production and a very high sales/cash flow break even point. This has recently changed with large cost cutting, successful sale of excess capacity (for $43million) that has negated the need for a rumoured CR.

New figures are showing they are now much closer to being cash flow positive and at their current rate of sales growth may be profitable by years end.

So people have started to come back to DNDN - the old link with Prima is not there anymore as the companies are in very different positions than they used to be (when DNDN was first getting FDA approval)

Prima will start to rise mid year hopefully until then good buying opportunity